Recognition of sex differences can promote a more personalized patient-centered care approach to ensure goals of therapy are achieved among patients prescribed antipsychotics. Read on to find out more.
Psychiatry residents working in psychiatric hospitals have encountered difficulties during the COVID-19 pandemic. The objective of this study was to identify the COVID-19-related stressors these young physicians are experiencing.
What is the difference between errors and discrepancies in radiological interpretations? How often do errors occur, and how can they be avoided? Explore these questions in this CME activity from Banner Alzheimer's Institute.
Diagnostic workup of early onset dementias often takes a circuitous route. Here, the authors demonstrate how clinically meaningful information can be gleaned from an inconclusive diagnostic workup using a longitudinal and multidisciplinary approach.
The quantification of antipsychotic levels in blood, or therapeutic drug monitoring (TDM), could aid clinicians in numerous challenging scenarios. Learn more about using TDM for dosing decisions in this journal CME activity that describes expert consensus.
Level of trust in medical professionals can alter health outcomes and influence doctor-patient relationships. This study utilized MRI and trust data from the Dallas Heart Study to determine brain regions associated with degree of trust in physicians.
Care coordination across health systems is critical to optimize patient care for chronic medical and psychiatric conditions. Group concept mapping provides a strategic process to allow shared decision making among stakeholders.
Could family physicians embedded in mental health institutions reduce the need to transfer patients out of the hospital to receive care for nonpsychiatric conditions? Read this interesting study to find out.
Have you ever wondered whether physicians have the right to restrict patients' behavior when they are voluntary inpatients? As a health care provider, have you been afraid to be flexible when enforcing rules imposed upon patients for fear of liability if a bad outcome were to arise? If you have, then this Rounds in the General Hospital article should prove useful.
Baclofen, a French Exception, Seriously Harms Alcohol Use Disorder Patients Without Benefit
To the Editor: Dr Andrade’s analysis of the Bacloville trial in a recent Clinical and Practical Psychopharmacology column, in which he concluded that “individualized treatment with high-dose baclofen (30-300 mg/d) may be a useful second-line approach in heavy drinkers” and that “baclofen may be particularly useful in patients with liver disease,” deserves comment.1
First, Andrade failed to recall that the first pivotal trial of baclofen, ALPADIR (NCT01738282; 320 patients, as with Bacloville), was negative (see Braillon et al2).
Second, Dr Andrade should have warned readers that Bacloville’s results are most questionable, lacking robustness. Although he cited us,3 he overlooked the evidence we provided indicating that the Bacloville article4 was published without acknowledging major changes to the initial protocol, affecting the primary outcome. Coincidentally (although as skeptics, we do not believe in coincidence), the initial statistical team was changed when data were sold to the French pharmaceutical company applying for the marketing authorization in France. As Ronald H. Coase warned, “If you torture the data long enough, it will confess.”